Clinical trial
Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma…
NCT00278122 · University of Virginia, Other · Suspended
Key facts
| NCT number | NCT00278122 |
|---|---|
| Title | Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery |
| Official title | Evaluation of the Clinical Efficacy of Leukine® Administered in Conjunction With Paclitaxel in Patients With Advanced Melanoma |
| Lead sponsor | University of Virginia, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Suspended |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological, Drug |
| Interventions | sargramostim, paclitaxel |
| Enrollment | 42 |
| Start date | Jul 1, 2005 |
| Primary completion | Dec 1, 2015 |
| First posted | Jan 18, 2006 |
| Last update posted | Dec 10, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: